Pioglitazone in addition to metformin improves erythrocyte deformability in patients with Type 2 diabetes mellitus (Q33590082)

28 July 2017

Pioglitazone in addition to metformin improves erythrocyte deformability in patients with Type 2 diabetes mellitus (English)

1 reference

28 July 2017

1 reference

1 reference

9

Andreas Pfützner

1 reference

28 July 2017

Thomas Forst

1

1 reference

28 July 2017

Matthias M Weber

2

1 reference

28 July 2017

Mirjam Löbig

3

1 reference

28 July 2017

Ute Lehmann

4

1 reference

28 July 2017

Jürgen Müller

5

1 reference

28 July 2017

Cloth Hohberg

6

1 reference

28 July 2017

Christiane Friedrich

7

1 reference

28 July 2017

Winfried Fuchs

8

1 reference

28 July 2017

language of work or name

English

0 references

publication date

9 July 2010

1 reference

28 July 2017

1 reference

28 July 2017

119

1 reference

28 July 2017

8

1 reference

28 July 2017

345-351

1 reference

C-peptide and its C-terminal fragments improve erythrocyte deformability in type 1 diabetes patients

28 July 2017

1 reference

https://api.crossref.org/works/10.1042%2FCS20100161

Association of reduced red blood cell deformability and diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100161

Organ preservation solutions impair deformability of erythrocytes in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100161

Microvascular impairment is associated with insulin resistance in euglycemic mild hypertensives

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100161

Relationship between hemorrheologic factors and insulin sensitivity in healthy young men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100161

Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100161

Short-term low-dosage pioglitazone treatment improves vascular dysfunction in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100161

Influence of glucose control and improvement of insulin resistance on microvascular blood flow and endothelial function in patients with diabetes mellitus type 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100161

Pioglitazone-induced insulin sensitization improves vascular endothelial function in nondiabetic patients with essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100161

Pioglitazone vs glimepiride: Differential effects on vascular endothelial function in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100161

Effect of simvastatin and/or pioglitazone on insulin resistance, insulin secretion, adiponectin, and proinsulin levels in nondiabetic patients at cardiovascular risk--the PIOSTAT Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100161

Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100161

Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100161

IRIS II study: intact proinsulin is confirmed as a highly specific indicator for insulin resistance in a large cross-sectional study design

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100161

Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality?: a meta-analysis of observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100161

The effect of human proinsulin C-peptide on erythrocyte deformability in patients with Type I diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100161

Parameterization of red blood cell elongation index--shear stress curves obtained by ektacytometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100161

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100161

The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100161

Pioneer study: PPARgamma activation results in overall improvement of clinical and metabolic markers associated with insulin resistance independent of long-term glucose control

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100161

Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100161

Adiponectin: protection of the endothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100161

Association of hypoadiponectinemia with impaired vasoreactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100161

Adiponectin levels and cardiovascular risk factors in Japanese men with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100161

Pharmacological PPARgamma stimulation in contrast to beta cell stimulation results in an improvement in adiponectin and proinsulin intact levels and reduces intima media thickness in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100161

Abnormalities of membrane function and lipid metabolism in hypertension: a review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100161

Adiponectin and membrane fluidity of erythrocytes in normotensive and hypertensive men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100161

Adiponectin stimulates production of nitric oxide in vascular endothelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100161

Haematocrit, type 2 diabetes, and endothelium-dependent vasodilatation of resistance vessels

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100161

Safety and tolerability of pioglitazone, metformin, and gliclazide in the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20100161

21 January 2018

Identifiers

DOI

10.1042/CS20100161

1 reference

28 July 2017

1 reference